XCancer

Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

Description:

The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.

Sponsor:

Turku University Hospital

Phase:

Phase 2/3

Contacts:

Heikki RI Minn, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01460706 - Click here to see study on

ClinicalTrials.gov

DOTATOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA
Inclusion
  • Language spoken: Finnish or Swedish
  • Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
  • Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
  • Supratentorial malignant glioma based on MRI imaging
  • * Age: 18 to 70 years old
Exclusion
  • Pregnant or lactating women
  • * Any medical or psychiatric condition that compromises the subject´s ability to participate in the study
  • Any other significant disease including liver or renal disease